Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system - Scorecard - MDSpire

Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system

  • By

  • José González Costello

  • Víctor Exposito Garcia

  • Eoin Moloney

  • Vasileios Kontogiannis

  • Mehdi Javanbakht

  • Farai Goromonzi

  • Brigitte Both

  • Raúl Moreno

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Economic Evaluation of Wearable Cardioverter Defibrillator Use in High-Risk Patients Following Myocardial Infarction within the Spanish Healthcare System

At a Glance

CategoryDetail
Condition
Key MechanismsWearable cardioverter defibrillator (WCD) provides temporary protection against sudden cardiac death during the early post-MI period, as supported by the VEST trial.
Target Population
Care Setting

Key Highlights

  • WCD plus guideline-directed medical therapy (GDMT) improves life years and quality-adjusted life years compared to GDMT alone, as per the study results.
  • Incremental cost-effectiveness ratio of €26,145 per QALY gained, based on the study's findings.
  • 78.3% probability of cost-effectiveness for early post-MI patients, according to the analysis.

Guideline-Based Recommendations

Diagnosis

    Management

    • C
    • o
    • n
    • s
    • i
    • d
    • e
    • r
    • W
    • C
    • D
    • u
    • s
    • e
    • a
    • l
    • o
    • n
    • g
    • s
    • i
    • d
    • e
    • G
    • D
    • M
    • T
    • f
    • o
    • r
    • p
    • a
    • t
    • i
    • e
    • n
    • t
    • s
    • a
    • t
    • h
    • i
    • g
    • h
    • r
    • i
    • s
    • k
    • o
    • f
    • s
    • u
    • d
    • d
    • e
    • n
    • c
    • a
    • r
    • d
    • i
    • a
    • c
    • d
    • e
    • a
    • t
    • h
    • ,
    • a
    • s
    • i
    • n
    • d
    • i
    • c
    • a
    • t
    • e
    • d
    • i
    • n
    • t
    • h
    • e
    • s
    • t
    • u
    • d
    • y
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        1,000 post-MI patients with reduced left ventricular ejection fraction

        WCD therapy shows potential to improve health outcomes at an incremental cost within willingness-to-pay thresholds

        Clinical Best Practices

        • Implement appropriate patient education and follow-up to enhance adherence to WCD therapy, as suggested by real-world evidence.
        • Utilize real-world evidence to inform clinical practice and model assumptions, based on findings from the study.

        Related Resources & Content

        Original Source(s)

        Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system

        • by José González Costello, Víctor Exposito Garcia, Eoin Moloney, Vasileios Kontogiannis, Mehdi Javanbakht, Farai Goromonzi, Brigitte Both, Raúl Moreno

        • May 29, 2026

        Related Content

        Case Report: Selective metal cell excision during open TAVR implantation preserves coronary access while maintaining valve integrity and function

        Differential biomarker responses of hemolysis, inflammation, and myocardial injury after pulsed-field pulmonary vein isolation: balloon-in-basket vs. circular catheter systems

        National trends and county-level geographic disparities in mortality from operationally defined cardiovascular–kidney–metabolic stages 4 and 4b in the United States